明志科大拓鴻途團隊與和康生技公司洽談人工骨材產線試量產合作
Bonactive Team, Ming Chi University of Science and Technology (MCUT) negotiated with Maxigen Biotech Inc. (MBI) for the trial production line for an artificial bone graft
由明志科技大學生醫博士學程師生組成的研發團隊於本(112)年12月29日進一步與和康生物科技公司洽談生物玻璃陶瓷產線試量產工廠合作內容。
明志科技大學表示，拓鴻途團隊是由該校生醫博士學程師生所組成，在學校資源挹注與輔導下，成功研發出「玻璃陶瓷複合材料之骨粉」，用自行研發高孔隙率複合陶瓷材料製成之骨粉，能釋放活性離子，比市面上現有的骨粉更具有強化骨整合速度的優勢，目前已進行到第三方生物相容性測試，並完成骨細胞分化與鈣化表現的動物驗證階段，也參與國科會FITI創新創業激勵計畫，進入全國前20強團隊，發展前景可期。
明志科技大學拓鴻途團隊指導教授陳炳宜表示，生物玻璃陶瓷合成骨材經過3年研發階段，成果獲肯定得到2023台灣創新技術博覽會銀牌獎，也獲得國科會112年度產學合作計畫成果發表暨績效考評會議-特優獎，拓鴻途團隊與和康生技的合作，能優化和康公司骨粉的產品功效與產品定位，後續與和康生技透過試量產工廠的合作希望將產品製程技術導入和康公司，是明志科大將商品化技術落地至實際商品化量產的另一個里程碑。
明志科技大學表示，讓學生所學有一個明確的出海口相當重要，因此透過校內產學發展中心輔導與補助以及外部各項資源鏈結，以作為學生的創業基金，也期待與和康生技互相善用彼此優勢，在共同的理念之下，持續深化彼此合作的關係，共同拓展更多商業契機。
The R&D team composed of professors and students of Ming Chi University of Technology's International Ph.D. Program in Biomedical Engineering negotiated with Maxigen Biotech Company on December 29, 2023. The content of the cooperation between the two entities is the trial production plant for the bioglass ceramic.
Ming Chi University of Technology said that the Bonactive Team is composed of professors and students of the university's International Ph.D. Program in Biomedical Engineering. With the aid of the university's resources, the team successfully developed the "Bone Powder of Glass-Ceramic Composites" made of self-developed high-porosity composite ceramic materials that is capable of releasing active ions and has the advantage of strengthening the osseointegration speed compared with the existing bone powder on the market. Bonactive Team also participated in the FITI Innovation and Entrepreneurship Incentive Program of the National Science and Technology Council and entered the top 20 teams in the country, with promising development prospects.
Prof. Pin-Yi Chen, the supervising professor of the Bonactive Team of Ming Chi University of Technology, said that after 3 years of research and development, the results of bioglass ceramic synthetic bone materials have been affirmed, and the team won the silver medal in the 2023 Taiwan Innovation Technology Expo. The team also won the Excellence Award in the 2023 Annual Industry-University Cooperation Plan Achievement Publication and Performance Appraisal Conference of the National Science and Technology Council. Furthermore, the cooperation between the Bonactive Team and MBI can optimize the product efficacy of Maxigen Biotech Company's bone graft product positioning. The cooperation with MBI for the trial production plant hopes to introduce the product process technology into MBI, which is another milestone for Ming Chi University of Technology to implement commercialization technology to actual commercial mass production.
Ming Chi University of Technology said that it is very important for students to have a clear outlet for what they have learned; hence, an avenue is provided to them through the guidance and subsidy of the university's Industry-University Development Center and the links of various external resources. The cooperation with Maxigen Biotech is also expected to make good use of each other's advantages and continue to deepen the cooperative relationship with each other under the common goal of developing a bone graft production line and jointly expand more business opportunities.
圖一：拓鴻途團隊陳炳宜老師(左五)與和康生技賴柏宏副總(佐四)及團隊合照
Picture 1: Group photo of Prof. Pin-Yi Chen (5th from the left) of the Bonactive team, Vice President Pai-Hong Lai (4th from the left) and the Maxigen Biotech team.
圖二：產發中心與拓鴻途團隊及和康生技會議合照
Picture 2: Group photo of the meeting held with the Industrial Development Center of MCUT, the Bonactive team, and the Maxigen Biotech team.